Arcturus Therapeutics HoldingsARCT -2.71%54 PB Ratio is 1.01 as of Jun. 25, 2026, which is 63% below its 10-year median of 2.70. GuruFocus rates ARCT with a GF Score™ of 54/100 and a GF Value™ of $4.41 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,233 Biotechnology companies, Arcturus Therapeutics Holdings ranks better than 81.75% on this metric.
The historical rank and industry rank for Arcturus Therapeutics Holdings's PB Ratio or its related term are showing as below:
ARCT'
s PB Ratio Range Over the Past 10 Years
Min: 0.67 Med: 2.7 Max: 52.03
Current: 1.01
During the past 13 years, Arcturus Therapeutics Holdings's highest PB Ratio was 52.03. The lowest was 0.67. And the median was 2.70.
ARCT's PB Ratio is ranked better than 81.75% of 1233
companies
in the Biotechnology industry
Industry Median: 2.8
vs ARCT: 1.01
During the past 12 months, Arcturus Therapeutics Holdings's average Book Value Per Share Growth Rate was -21.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -9.60% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -9.20% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 17.30% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Arcturus Therapeutics Holdings was 154.30% per year. The lowest was -74.80% per year. And the median was 1.00% per year.
Back to Basics: PB Ratio
Arcturus Therapeutics Holdings (NAS:ARCT) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Arcturus Therapeutics Holdings PB Ratio Related Terms
Arcturus Therapeutics Holdings PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Arcturus Therapeutics Holdings's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arcturus Therapeutics Holdings PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arcturus Therapeutics Holdings's PB Ratio distribution charts can be found below:
* The bar in red indicates where Arcturus Therapeutics Holdings's PB Ratio falls into.
Arcturus Therapeutics Holdings PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Arcturus Therapeutics Holdings (ARCT) has a PB Ratio of 1.01 as of Jun. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Arcturus Therapeutics Holdings and its competitors. This is 63% below median its historical median of 2.70. Over the past decade, Arcturus Therapeutics Holdings' PB Ratio has ranged from 0.67 to 52.03. According to the industry distribution chart, Arcturus Therapeutics Holdings ranks #225 out of 1233 companies in the Biotechnology industry, placing it in the top 18.2%.
Is Arcturus Therapeutics Holdings' PB Ratio too high?
Arcturus Therapeutics Holdings' current PB Ratio of 1.01 is 63% below median its 10-year median of 2.70. Over the past 10 years, this metric has ranged from a low of 0.67 to a high of 52.03. The Biotechnology industry median PB Ratio is 2.80. Arcturus Therapeutics Holdings' value of 1.01 is 63.9% below this industry median. Based on the distribution chart, Arcturus Therapeutics Holdings ranks #225 out of 1233 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Arcturus Therapeutics Holdings has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Arcturus Therapeutics Holdings' PB Ratio compare to YDES and RNAC?
According to the Biotechnology industry distribution chart, Arcturus Therapeutics Holdings ranks #225 out of 1233 companies for PB Ratio. This places Arcturus Therapeutics Holdings in the top 18% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.80. Arcturus Therapeutics Holdings' value of 1.01 is 63.9% below this benchmark. Historically, Arcturus Therapeutics Holdings' own PB Ratio has ranged from 0.67 to 52.03 over the past decade. While the company's 10-year median is 2.70 vs. the industry median of 2.80, Arcturus Therapeutics Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,233 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Arcturus Therapeutics Holdings's current PB Ratio of 1.01 is 63.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Arcturus Therapeutics Holdings and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arcturus Therapeutics Holdings's current PB Ratio is 1.01, which is 63% below median its own 10-year median of 2.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arcturus Therapeutics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Arcturus Therapeutics Holdings (ARCT) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.41, compared to a current price of $6.82 — trading 54.5% above its estimated fair value. The current PB Ratio is 1.01, which is 63% below median its 10-year median of 2.70 and 63.9% below the Biotechnology industry median of 2.80. Arcturus Therapeutics Holdings' overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Arcturus Therapeutics Holdings (ARCT), the current PB Ratio is 1.01 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arcturus Therapeutics Holdings (ARCT) Overvalued in 2026?
Based on GuruFocus' analysis, Arcturus Therapeutics Holdings stock appears to be overvalued.
The current stock price of $6.82 is trading 54.5% above its estimated GF Value™ of $4.41.
GuruFocus considers Arcturus Therapeutics Holdings to be Significantly Overvalued.
Key valuation signals for ARCT:
PB Ratio: 1.01 (63% below median its 10-year median of 2.70)
GF Value™: $4.41 vs. price of $6.82 (54.5% above fair value)
Industry Position: 63.9% below the Biotechnology median (#225 of 1233)
No single metric tells the full story. See the ARCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arcturus Therapeutics Holdings Business Description
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.
54GF Score
Get the complete analysis for ARCT
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARCT has been successfully added to your 
